Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and PK of G01 Eye Drops in Healthy Subjects
NCT07779902Phase 1Completed
- Sponsor
- Qingdao Wanming Bio-Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing G01 Eye Drops with Placebo (2 arms). Primary endpoints: Number of Participants With Adverse Events and Number of Participants With Clinically Significant Abnormalities in Safety Assessments. Started Dec 2024; status: completed.
02
Drugs
G01 Eye Drops
Beyond the preview
Go deeper on NCT07779902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07779902.